Longevity is an economic policy now

10 Years ago I wrote an article arguing that a region should stop chasing the dream of becoming the next Silicon Valley and instead pick one niche, wrap it in a regulatory sandbox, and become the world's test centre for it. The piece even helped spark HealthTech.Belgium, a coalition of partners who believed this country could be that place for digital health. It didn't last. The idea felt right and about a decade early, which in my experience usually reads as: 'wrong'.

On 10 June, Dubai showed it was only early. Sheikh Mohammed bin Rashid issued Law No. 17 of 2026 establishing the Dubai Longevity Authority, a sovereign body whose entire job is to make the emirate the world's leading hub for regulated longevity, wellness and advanced healthcare. I have read a lot of government innovation announcements. This one made me sit up, because of a single structural detail.

Dubai's new longevity regulator is not chaired by a health minister. It is chaired by the man who runs the Department of Economy and Tourism.

That choice is the whole thesis. The chairman is Helal Saeed Almarri, head of Dubai's economy and tourism portfolio, and the authority is built to serve the emirate's D33 economic agenda. Almarri described the goal as building "a sophisticated, sovereign market for advanced therapeutic products and services" designed to attract investment, industrial capability and specialised talent, and to move real technology and business models "into the economy" (The National). Read it again: health is the product, the economy is the point.

Why this is smarter than it looks

A region that bets on longevity collects a multi-edged return. Healthier citizens live longer, more active lives, so chronic-disease costs fall and people stay productive deeper into their careers. A clear sandbox attracts the companies, talent and capital that want fast, predictable approval pathways. And the expertise that builds up becomes an export product in its own right: clinics, protocols, devices, training programmes. That is one investment paying off in four directions at once.

The Gulf is not being shy about it. Saudi Arabia's Hevolution Foundation has committed up to $1 billion a year to healthspan research. Abu Dhabi is licensing dedicated longevity-medicine centres and building a flagship longevity resort. Dubai now frames the prize as an $8 trillion healthy ageing market. As one widely shared post on X put it this month, the anti-ageing race "just went geopolitical": sovereign wealth, zero taxes, and some of the fastest clinical-trial approvals in the world. When governments start treating longevity as a strategic asset, the research clock speeds up.

Where is Europe in all this?

This is the part that should bother anyone reading from Brussels, Berlin or Bologna. Europe has the science, the universities and arguably the richest public-health data on the planet. What it does not have is a sovereign bet. Our 2026 conversation runs on energy shocks, defence budgets and ageing treated as a fiscal drag on pensions. Prevention gets discussed as a cost to contain rather than an industry to build. Even the sharpest European voices are still at the "case we cannot afford to ignore" stage, while Dubai has already signed the law and put its crown prince at the top of it.

And the cost framing is getting harder to defend. Three days before this piece went out, the World Economic Forum published a report titled, with no apparent irony, The Longevity Dividend: The Business Case for Linking Health and Wealth. Its finding reads as a direct rebuttal: low-tech, low-cost measures (home-safety retrofits, community exercise programmes, wider hearing-aid access) could unlock $5.8 trillion in healthcare savings and $645 billion in productivity gains by 2040, if governments stop running health, finance and labour as separate budgets. The European example makes it sting; in the Netherlands, widening hearing-aid access alone could prevent over 8,000 dementia cases and save $2 billion. The Forum now even staffs a "Lead, Longevity Economy". The prize is quantified, the levers are cheap, and the institutions that grade economies have started counting it. What is missing in Europe is not the business case. It is the decision to act on it.

I am not romanticising the model. A state-led, top-down strategy that imports its talent has obvious limits, and a light-touch sandbox raises fair questions about evidence and patient safety. But "they move too fast" is a weak defence when your own alternative is barely moving at all.

So here is the uncomfortable question for European leaders. If ageing is the one demographic certainty every country shares, why is it filed under cost almost everywhere except the places that decided to make it an industry?

The longevity dividend is real, and it will not turn up in Europe by accident. It lands where someone writes the law, builds the regulator, and decides that keeping people healthy is an economic strategy and not a line in the welfare budget. Dubai just made that decision in public.

Europe's version doesn't have to copy that model. The contrarian bet is the opposite shape: a federated, open-source sandbox where the data stays home, the standards are shared, and anyone from a teaching hospital to a two-person startup to a determined individual can experiment on a level field. That's a thread for another day.

If you want to see where this energy already shows up, in the conferences, capital and clinics that signal where the money is heading, that is exactly what we map at Longevity Events, including how Europe stacks up against the rest of the field.

Next experiment for your own organisation or region: name the one health niche where you already hold an unfair advantage, whether that is data, talent, a patient population or a willing regulator. Then ask what a sandbox built around it would actually require. You don't need a sovereign wealth fund to begin. You need a decision.

💥 May this inspire you to treat health as the economic engine it already is.